45results about How to "Break immune tolerance" patented technology

Stimulation of T cells to respond to self antigens is achieved through a blockade of CTLA-4 signaling. CTLA-4 blocking agents are combined with antigen preparations, either alone or with additional immune response stimulating agents, in costimulation strategies to break immune tolerance and stimulate an enhanced T-cell response against self antigens. This enhanced response is useful for the treatment of non-immunogenic and poorly-immunogenic tumors, as well as other medical conditions requiring selective tissue ablation.

The invention relates to an antitumor cell immunotherapy technology, in particular to preparation of a specific tumor killing cell. The preparation method disclosed by the invention comprises the following steps of: 1, sampling a single prokaryotic cell from peripheral blood; 2, separating a DC (Dendritic Cell) from a T cell; 3, maturing the DC and preparing a DC vaccine; 4, preparing a CIK (Cytokine Induced Killer); 5, preparing a CTL (cytotoxic T lymphocyte); and 6, preparing a specific DC-CIK-CTL cell preparation.

The invention discloses a compound-type nano-vaccine taking an amphiphilic three-block polymer of polyethylene glycol derivative-poly lysine-poly leucine as a nano-carrier bearing a tumor antigen, an immunological adjuvant and siRNA (si Ribonucleic Acid), and a preparation method of the compound-type nano-vaccine. According to the nano-vaccine, taking and presenting of the antigen by antigen-presenting cells can be improved by a nano-micelle bearing the antigen; siRNA is efficiently delivered to TADCs (Tumor-associated Dendritic Cells) to block immunosuppression signals of TADCs, and TADCs are induced and activated by collaboration with the immunological adjuvant, so that a tumor resisting effect of a tumor vaccine is improved; the nano-vaccine has the advantages that the adopted carrier of the nano-vaccine is good in biocompatibility and low in toxicity, and is degradable in a biological body; degradation products are nontoxic and harmless, and can be absorbed or metabolized; and the preparation method of the nano-vaccine is simple and convenient and feasible, good in stability and convenient for popularization.

The present invention relates to one kind of and its preparation and use, and belongs to the field of biotechnology. The HIV-1 virus-like particle contains complete core protein gag, encoding enzyme protein pol and outer membrane protein env of HIV-1, and is nonreplication type. The present invention is superior in that stably expression cell line is established through cotransfection and monoclonal cell screening. The cell line can secrete HIV-1 virus-like particle stably and continuously, and the HIV-1 virus-like particle contains no virus nucleic acid and has high safety. The constituted VLP has reasonable assembling form and high similarity with natural virus in structure, and may be used as HIV-1 treating vaccine.

The invention relates to a cervical cancer therapeutic vaccine based on recombinant attenuating sheep listeria ivanovii. By taking the attenuating sheep listeria ivanovii as a vector, specific immuneresponse in a tumor microenvironment is improved effectively and immune tolerance of a body is broken by means of a unique characteristic that the listeria ivanovii can grow in a main phagocyte and isa natural T cell immune activation adjuvant, so that continuous virus infection of the body is eliminated and the good therapeutic effect of eliminating the focus and inhibiting tumor development isachieved. The vaccine has the advantages that the defect that nucleic acid and protein polypeptide vaccines are relatively low in immunogenicity is made up, and the attenuating sheep listeria ivanoviialso has high safety while retaining the characteristic that an original strain can grow in cells to achieve antigen presentation.

The invention relates to a cervical cancer therapeutic vaccine based on recombinant attenuated Listeria monocytogenes. Attenuated Listeria monocytogenes (hereinafter referred to as Lm) is used as a vector, and the unique ability of Listeria to grow in a host phagocytic cell is the characteristic of a natural T cell immune activation adjuvant, and is used to effectively improve the specific immuneresponse in a tumor microenvironment and break the immune tolerance of bodies, so persistent viral infection of the bodies is removed, and good therapeutic effects of clearing focus and restraining tumor development are achieved. The cervical cancer therapeutic vaccine makes up for the shortcoming of low immunogenicity of nucleic acid and protein peptide vaccines, and the attenuated Listeria reserves the intracellular growth and antigen presentation completion characteristics of an original strain, and has a high safety.

The invention belongs to the field of biological medicines, and concretely relates to a novel asthma polypeptide vaccine and a preparation method thereof. The invention aims to solve the technical problem so as to provide a new effective selection for asthma treatment in the field. The technical scheme provided by the invention for solving the technical problem is characterized by connecting DiTOX polypeptide or PADRE polypeptide on a nitrogen end of E3 polypeptide to obtain a new fusion polypeptide, wherein the polypeptide can be used as a main active constituent for preparing the asthma vaccine. The polypeptide vaccine provided by the invention can effectively induce specific humoral immunity, can break immune tolerance, and has a better application prospect when being used as the polypeptide vaccine for asthma treatment.

The invention relates to an antigen epitope, in particular to an immune dominant HLA-A3 (human leukocyte antigen A3) super-type restrictive CTL (cytotoxic T lymphocyte) epitope of a hepatitis B virus core antigen (HBcAg) and an identification method for the super-type CTL epitope. The super-type CTL epitope consists of the following amino acid sequence: Leu-Leu-Asp-Thr-Ala-Ser-Ala-Leu-Tyr-Arg. The method is also suitable for identification of other antigen super-type CTL epitopes, and can provide a useful tool for design and research of therapeutic polypeptide vaccines. The invention also relates to application of the super-type CTL epitope in preparing hepatitis B therapeutic polypeptide vaccines, and provides a new strategy and a new method for efficient research of the hepatitis B therapeutic polypeptide vaccines. The method is expected to break through hepatitis B immune tolerance, reconstruct the immune function of cells and efficiently inhibit and clear hepatitis B viruses.

The invention relates to a double-target CAR-T therapy vector for colon cancer, and a construction method and application of the double-target CAR-T therapy vector. The double-target CAR-T therapy vector consists of two parts comprising a lentiviral expression vector pCDH-EF1aplpha-MCS-(PGK-Puro) and a CAR structure. The specific structure of the CAR is Igkappa-iRGD-CEAscFv-(G<4>S)<5>-Her-2scFv-CD8alpha-CD28-CD137-CD3zeta-T2A-CCL19. A T cell containing the therapy vector, namlely the CAR-T cell (Chimeric Antigen Receptor T-Cell), is obtained through the mode of virus infection, and the CAR-T cell can be used for targeted identification and killing of colon cancer cells by expressing the CAR structure.

The invention discloses a vector containing a double-target chimeric antigen receptor gene, a CAR-T cell and application of the CAR-T cell. The double-target chimeric antigen receptor is formed by sequentially splicing signal peptides, CD44 single-chain antibody ScFv, EpCAM single-chain antibody ScFv, strepII tag, CD8 molecular hinge region, CD28 molecular transmembrane region, intracellular structural domain of the CD28 molecular transmembrane region, intracellular costimulatory domain 4-1BB and CD3 molecular zeta chain from an N end to a C end. Meanwhile, a lentivirus expression recombinantplasmid pTK-881-CD44-EpCAM is constructed, lentivirus packaging is carried out, T cells are infected, and the double-target-point CAR-T cells capable of removing CD44 and EpCAM at the same time are obtained. Based on a CAR-T technology, gastric cancer stem cells are killed by only utilizing autoimmunity of a patient, so that a doctor is assisted in gastric cancer treatment.

The invention discloses an enhanced bivalent DC (dendritic cell) vaccine of human papillomavirus HPV-16/18, comprising genetically-modified dendritic cells, recombinant gene sequences in the genetically-modified dendritic cells are serially connected via granulocyte-macrophage stimulating factor and L1 transcription regions of human papillomavirus HPV-16/18, and the DC vaccine is composed of genetically-modified DC surface antigen, comprising granulocyte-macrophage stimulating factor expressed via an enhancement antigen, and L1 antigen proteins of human papillomavirus HPV-16/18. The DC vaccine is a prevention and treatment vaccine, capable of effectively preventing HPV-16 and HPV-18 infections and related diseases caused by HPV infections.

The invention relates to application of recombinant attenuated listeria in the preparation of a mesothelin high-expression cancer therapeutic vaccine. By taking attenuated Listeria monocytogenes (Lm for short hereinafter) and attenuated Listeria ivanovii (Li for short hereinafter) as carriers, and special listeria can grow in phagocyte of a host and is a natural T-cell immune activation adjuvant,so that the specific immune response in a tumor microenvironment is effectively improved, the immune tolerance of a body is broken through, the continuous virus infection of the body is eliminated, and good treatment effects on the elimination of an infection focus and the containment of tumor development are achieved. The application has the advantages that the disadvantages that nucleic acid type vaccines and protein polypeptide type vaccines are relatively low in immunogenicity are remedied, the attenuated listeria preserves the properties that an original strain can grow in the cells and finish antigen presentation, and meanwhile, the attenuated listeria has relatively high safety.

The invention relates to application of recombinant attenuated Listeria in preparation of a therapeutic vaccine for cervical cancer. Attenuated Listeria monocytogenes (hereinafter referred to as Lm) and attenuated Listeria ivanovii (hereinafter referred to as Li) are used as vectors, by use of the unique characteristic that the Listeria can grow in phagocytose cells in a host, and is a natural T cell immune activation adjuvant, specific immune response in tumor microenvironment can be effectively enhanced, body's immune tolerance can be broken, body's persistent viral infection can be eliminated, and good treatment results of clearing focuses and curbing tumor development can be achieved. The Listeria has the advantages that shortcomings of low immunogenicity of nucleic acid and protein peptide vaccines can be made up, the attenuated Listeria retains the characteristic that an attenuated original strain can grow intracellularly to complete antigen presentation, and meanwhile the attenuated Listeria has higher safety.

The invention belongs to the field of biological medicines, and relates to a mutant protein vaccine aiming at tumor necrosis factor alpha (TNF-alpha) and applications of the mutant protein vaccine. The invention aims at providing the protein vaccine which is good in property and takes TNF-alpha as the target spot. According to the scheme, by immunizing the TNF-alpha mutant protein vaccine, the biological activity of the TNF-alpha mutant protein vaccine is inhibited, the cross immunologic reaction is generated in vivo, the biological functions of TNF-alpha are neutralized, and the autoimmune diseases and inflammatory diseases are inhibited. The protein vaccine aiming at TNF-alpha can be used for treating the autoimmune diseases and the inflammatory diseases and preventing the relapse of the autoimmune diseases and the inflammatory diseases.

The invention provides a dual-target CAR-T therapeutic vector for breast cancer and a construction method and application thereof. The dual-target CAR-T therapeutic vector consists of a lentiviral expression vector pCDH-EF1 alpha-MCS-(PGK-Puro) and a CAR structure. The CAR structure is specifically Igkappa-iRGD-mesothelin scFv-(G4S)5-CD133scFv-CD8 alpha-CD28-CD137-CD3 zeta-2A-CCL19. A virus infection mode is adopted to obtain a T cell containing the therapeutic vector, namely a CAR-T cell (Chimeric Antigen Receptor T-Cell), and breast cancer cells can be recognized and killed in a targeted mode through expression of the CAR structure.

The invention relates to a mesothelin high-expression cancer treatment vaccine based on recombinant attenuated listeria monocytogenes. The attenuated listeria monocytogenes (Lm) is used as a carier, the characteristics that the Lm can specifically grow in a host phagocyte and is a natural T cell immune activated reagent are utilized, specific immune response in a tumor microenvironment can be effectively improved, the immune tolerance of a body can be broken, persistent viral infection of the body can be cleaned, and an excellent treatment effect for cleaning the focus and inhibiting tumor development can be achieved. The mesothelin high-expression cancer treatment vaccine has the advantages of overcoming the defect of relatively low immunogenicity of nucleotide and protein polypeptide vaccines, the attenuated listeria remained with original strains can grow in cells, so that higher safety is achieved while the characteristic of antigen presentation can be completed.

The invention relates to the technical field of biology, in particular to a TEM-1 targeted gene vaccine and construction and application thereof. According to the gene vaccine, a flagellin (SF) is used as an adjuvant, rTEM-1 is used as an antigen, and a rTEM-1-SF fusion gene is obtained, and is constructed in eukaryotic expression plasmids pcDNA3.1. The rTEM-1/ flagellin fusion gene vaccine can restrain formation of tumor vessels of breast cancer tumor-bearing mice, the size of the tumor and transfer of the tumor, can restrain the transfer of breast cancer cells to lung tissue and liver tissue, and has the effects of preventing and treating the breast cancer.

The present invention provides a peptide having high binding affinity for PD-L1 protein and use thereof. The peptide has an amino acid sequence of SEQ. ID. NO. 1, SEQ. ID. NO. 3 or SEQ. ID. NO. 4, or the peptide is a tandem or branched peptide with a single repeat or multiple repeats of SEQ. ID. NO. 1, SEQ. ID. NO. 3 and SEQ. ID. NO. 4 and has an amino acid sequence of SEQ. ID. NO. 5. The peptide can bind to human PD-L1 with high affinity, competitively block the affinity of PD-1/PD-L1 protein, block the negative regulatory tolerance pathway of human tumors, activate immunity and increase the lethality of T cells against tumor cells.

The invention relates to the field of biological preparations, in particular to a pharmaceutical composition containing rhIL-12 for treating inactive hepatitis B. The pharmaceutical composition, in terms of each milliliter, consists of 10-20 [mu]g of recombinant human interleukin-12, 10-60 [mu]g of a recombinant HBsAg protein vaccine, 5-20 [mu]g of a cow mycobacteria vaccine and the balance of a water solution. The pharmaceutical composition is capable of activating a T achroacyte subgroup, promoting CD3+CD4+ and CD3+CD8+ cells to secrete IFN-[gamma] and inhibiting PD-1 expression of the CD3+CD4+ and CD3+CD8+ cells; in addition, the pharmaceutical composition can also activate mononuclear cells and dendritic cells, promote CD14+ cells and CD1a+ cells to express Toll-like receptors and enhance specific immunity and non-specific immunity functions, so as to break through an immune tolerance state and to better cure HBV infection; and in addition, the pharmaceutical composition can promote HBsAg seronegative conversion.